Health Care Related Organization – Page 17

Sanofi and Johnson & Johnson’s E. coli Vaccine Candidate Fails in Phase 3 Trial

4 months ago talkbio0Tagged E. coli disease, Escherichia coli, ExPEC9V, Failure (biologic function), Invasive, Johnson & Johnson, Phase 3 trial, sanofi, Vaccines

E. coli vaccine, Sanofi, Johnson & Johnson, Phase 3 trial failure, invasive E. coli disease, ExPEC9V

Newleos Therapeutics Launches with $93.5M to Develop Novel Neuropsychiatric Treatments

4 months ago talkbio0Tagged Anxiety Disorders, Clinical Trials, GABA A, Longwood Fund, Neuropsychiatry, Newleos, Roche (company), Substance Use Disorders

Newleos Therapeutics, Longwood Fund, neuropsychiatry, anxiety disorders, substance use disorders, Roche, GABA A -γ1, clinical trials

Sanofi’s E. coli Vaccine Fails Phase 3 Trial, Resulting in $250M Impairment Charge

4 months ago talkbio0Tagged charge amounts, Clinical Trials, Escherichia coli, Failure (biologic function), Impaired, Johnson & Johnson, Phase 3, sanofi, Vaccines

Sanofi, Johnson & Johnson, E. coli vaccine, Phase 3 failure, impairment charge, clinical trial discontinuation

FDA Approves Evrysdi Tablets: A Breakthrough in Convenient SMA Treatment

4 months ago talkbio0Tagged Approved, Drug Formulation Process, Evrysdi, genentech, Oral treatment, Risdiplam, Roche (company), Spinal Muscular Atrophy, Tablet Dosage Form, United States Food and Drug Administration

Evrysdi, risdiplam, spinal muscular atrophy (SMA), FDA approval, tablet formulation, oral treatment, Genentech, Roche

Vertex COO Stuart Arbuckle to Retire as Company Launches Groundbreaking Pain Drug Journavx

4 months ago talkbio0Tagged acute pain treatment, Approved, Arbuckle, Journavx, non-opioid pain medication, Retirement, Stuart Pharmaceuticals, United States Food and Drug Administration

Vertex Pharmaceuticals, Stuart Arbuckle, retirement, Journavx, non-opioid pain medication, FDA approval, acute pain treatment

Pharma Ads Make Waves at Super Bowl 2025: Pfizer Wins Hearts, Hims & Hers Drives Engagement

4 months ago talkbio0Tagged Awareness, Dosage Forms, Health care facility, likeability, Malignant Neoplasms, Pfizer, Super Bowl 2025, Viewer Device, Weight-Loss Agents

Super Bowl 2025, pharmaceutical advertising, Pfizer, Hims & Hers, ad likeability, viewer engagement, healthcare marketing, cancer awareness, weight loss drugs

Merck KGaA in Advanced Talks to Acquire SpringWorks Therapeutics, Bolstering Oncology Portfolio

4 months ago talkbio0Tagged Acquisition, Drug Industry, Gomekli, Merck KGaA, Neoplasms, Ogsiveo, SpringWorks

Merck KGaA, SpringWorks Therapeutics, acquisition, oncology, rare diseases, Ogsiveo, Gomekli, pharmaceutical industry

J&J’s Swift $14.6B Acquisition of Intra-Cellular Therapies: A CEO-Driven Deal

4 months ago talkbio0Tagged Acquisition, Caplyta, Drug Industry, Duato, Intra-Cellular Therapies, Joaquin, Johnson and Johnson, M&A, Neuroscience discipline

Johnson & Johnson, Intra-Cellular Therapies, acquisition, neuroscience, CAPLYTA, Joaquin Duato, pharmaceutical industry, M&A

Roche’s Gazyva Shows Promising Results in Phase III Lupus Nephritis Trial

4 months ago talkbio0Tagged Autoimmune Diseases, Gazyva, Lupus Nephritis, obinutuzumab, Phase III REGENCY trial, Renal function, renal response, Roche (company)

Gazyva, obinutuzumab, lupus nephritis, Phase III REGENCY trial, complete renal response, Roche, autoimmune disease, kidney function

Bain Capital Acquires Mitsubishi Tanabe Pharma for $3.3 Billion in Strategic Japanese Pharma Investment

4 months ago talkbio0Tagged Acquisition, Bain Capital, carve-out, Drug Industry, Investments, Japanese language, Mitsubishi, Private Equity, Transaction

Bain Capital, Mitsubishi Tanabe Pharma, acquisition, Japanese pharmaceutical industry, carve-out transaction, private equity, life sciences investment